JAKAVI Royalty Revenues — Total revenues
Incyte JAKAVI Royalty Revenues — Total revenues decreased by 18.9% to $105.56M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.6%, from $92.15M to $105.56M. Over 4 years (FY 2021 to FY 2025), JAKAVI Royalty Revenues — Total revenues shows an upward trend with a 7.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption and sales growth of the drug in the partner's territories, while a decrease may signal market saturation, increased competition, or patent expirations.
Detailed definition
This metric represents the total royalty income generated from the licensing and commercialization of a specific pharmac...
Peer comparison
Comparable to royalty revenue streams reported by other biotechnology firms that utilize out-licensing models to monetize their intellectual property in global markets.
incy_segment_jakavi_royalty_revenues_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $82.04M | $94.66M | $95.70M | $70.87M | $83.71M | $85.81M | $91.19M | $76.69M | $90.45M | $96.55M | $103.89M | $89.60M | $99.32M | $115.74M | $114.19M | $92.15M | $109.71M | $125.65M | $130.23M | $105.56M |
| QoQ Change | — | +15.4% | +1.1% | -25.9% | +18.1% | +2.5% | +6.3% | -15.9% | +17.9% | +6.7% | +7.6% | -13.8% | +10.9% | +16.5% | -1.3% | -19.3% | +19.1% | +14.5% | +3.6% | -18.9% |
| YoY Change | — | — | — | — | +2.0% | -9.3% | -4.7% | +8.2% | +8.0% | +12.5% | +13.9% | +16.8% | +9.8% | +19.9% | +9.9% | +2.8% | +10.5% | +8.6% | +14.0% | +14.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's jakavi royalty revenues — total revenues?
- Incyte (INCY) reported jakavi royalty revenues — total revenues of $105.56M in Q1 2026.
- How has Incyte's jakavi royalty revenues — total revenues changed year-over-year?
- Incyte's jakavi royalty revenues — total revenues increased by 14.6% year-over-year, from $92.15M to $105.56M.
- What is the long-term trend for Incyte's jakavi royalty revenues — total revenues?
- Over 4 years (2021 to 2025), Incyte's jakavi royalty revenues — total revenues has grown at a 7.9% compound annual growth rate (CAGR), from $337.99M to $457.73M.
- What does jakavi royalty revenues — total revenues mean?
- The total royalty payments received from a partner for the sales of a specific licensed pharmaceutical product.